Andrew J. Grethlein
Known title: EVP, Chief Operating OfficerCIK: 0001270921
Associated companies
Transaction History
| GERN | ▲ Buy | Option Exercise | 674,348 | $1.2M | 7/8/2024 | View on chart |
| GERN | ▼ Sell | Open Market | 674,348 | $3.1M | 7/8/2024 | View on chart |
| GERN | ▲ Buy | Option Exercise | 150,000 | $227K | 2/9/2023 | View on chart |
| GERN | ▼ Sell | Open Market | 150,000 | $454K | 2/9/2023 | View on chart |
| GERN | ▼ Sell | Open Market | 234,719 | $711K | 2/9/2023 | View on chart |
| GERN | ▲ Buy | Option Exercise | 2,000 | $3K | 9/12/2022 | View on chart |
| GERN | ▲ Buy | Option Exercise | 232,719 | $396K | 9/12/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
GERN Highlights Imetelstat at International Hematology Congresses
Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.
GERN Highlights Imetelstat at International Hematology Congresses. Geron Corporation announced that it will give oral presentations on its drug Imetelstat at international hematology congresses in Europe and Asia. The presentations are part of the company’s effort to advance Imetelstat’s clinical development and share results with the medical community. The news comes as the stock trades near its 52‑week low and around a $1.40 support level, with recent signals indicating a revenue‑price divergence.